** Shares of Maze Therapeutics MAZE.O rise 4.8% to $11.34
** Wall Street brokerages start coverage of the drug developer on a bullish note as IPO research quiet period ends
** J.P. Morgan starts coverage with "overweight" rating and $30 PT, a 177.2% upside to the stock's last close
** "With data for MZE829 available, we see its potential in addressing a wide population, competitive pricing, market share, and high success probability as key factors for boosting MAZE shares" - J.P. Morgan analysts referring to co's kidney disease therapy candidate
** Leerink Partners starts coverage with "outperform" rating and PT of $28, a 158.8% upside to the stock's last close
** "Chronic kidney disease represents a significant market opportunity, especially considering the major drain on overall Medicare spending. We assume gross peak sales of ~$1.8B in CKD" - Leerink Partners
** J.P. Morgan, TD Cowen, Leerink Partners and Guggenheim Securities were the underwriters for the IPO
** Stock has fallen 32% since its Nasdaq debut in January
(Reporting by Padmanabhan Ananthan)
((Padmanabhan.Ananthan@thomsonreuters.com;))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.